| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/02/2006 | US20060024322 Novel prophylactics/remedies for immunopathy |
| 02/02/2006 | US20060024321 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies |
| 02/02/2006 | US20060024320 Attenuated pestiviruses |
| 02/02/2006 | US20060024315 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/02/2006 | US20060024314 Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics |
| 02/02/2006 | US20060024310 Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides |
| 02/02/2006 | US20060024309 administering vascular endothelial growth factor (VEGF) antagonists such as VEGF fusion protein traps, nucleotides, antisense agents, lipids or carbohydrates, for decreased serum glucose levels, improved glucose tolerance, and/or improved glycemic control; antidiabetic agents |
| 02/02/2006 | US20060024299 Human osteoclast derived cathepsin |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024290 prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics |
| 02/02/2006 | US20060024289 Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
| 02/02/2006 | US20060024288 tRNA synthetase fragments |
| 02/02/2006 | US20060024287 Compositions and methods for modulating angiogenesis |
| 02/02/2006 | US20060024286 Variants of tRNA synthetase fragments and uses thereof |
| 02/02/2006 | US20060024285 Carcinogen detoxification composition and method |
| 02/02/2006 | US20060024284 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/02/2006 | US20060024283 Red blood cells loaded with S-nitrosothiol and uses therefor |
| 02/02/2006 | US20060024277 Method of skin care and/or treatment using extracts enriched in mitochondria |
| 02/02/2006 | US20060024275 Methods for use of MPL ligands with primitive human stem cells |
| 02/02/2006 | US20060024272 C-terminally truncated interferon |
| 02/02/2006 | US20060024271 Treatments for viral infections using IFN cytokines and ribavirin, alone or in combination |
| 02/02/2006 | US20060024270 Compositions and methods for preventing or treating encephalitis with interferon |
| 02/02/2006 | US20060024269 Treating cancer, inhibiting cancer progression and reducing side effects by administering an interleukin having a specific sequence and optionally polyethylene glycol (monomethoxy-polyethylene glycol propionaldehyde) that may be covalently linked amino-terminally to the polypeptide |
| 02/02/2006 | US20060024268 Modulation of immunoglobulin production and atopic disorders |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024242 Solubilizing liquid of refractory element and producing method thereof |
| 02/02/2006 | US20060024234 Protein markers for pharmaceuticals and related toxicity |
| 02/02/2006 | US20060024229 Method and product for locating an internal bleeding site |
| 02/02/2006 | CA2589098A1 Method for diagnosing and treating bone-related diseases |
| 02/02/2006 | CA2587019A1 Combination anticancer therapy and pharmaceutical compositions therefore |
| 02/02/2006 | CA2575356A1 Use of llt1 and/or cd161 for modulating the activity of cells of the immune system |
| 02/02/2006 | CA2575086A1 Compositions and methods for viscosupplementation |
| 02/02/2006 | CA2574959A1 Antimicrobial peptides derived from cap18 |
| 02/02/2006 | CA2574907A1 Physiologically-active composition based on collagen |
| 02/02/2006 | CA2574777A1 Actrii receptor polypeptides, methods and compositions |
| 02/02/2006 | CA2574773A1 Compositions and methods for treating excessive bleeding |
| 02/02/2006 | CA2574709A1 Treatment of renal dysfunction and multiple myeloma using pacap compounds |
| 02/02/2006 | CA2574564A1 Use of il-28 and il-29 to treat cancer and autoimmune disorders |
| 02/02/2006 | CA2572239A1 B7-h5, a costimulatory polypeptide |
| 02/01/2006 | EP1621633A2 Glycoproteins produced in plants with suppressed expression of beta 1, 2-xylosyltransferase |
| 02/01/2006 | EP1621628A2 Talaromyces emersonii beta-glucanases |
| 02/01/2006 | EP1621627A2 Use of porcine gala (1,3) galactosyl transferase in xenograft therapies |
| 02/01/2006 | EP1621620A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/01/2006 | EP1621619A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/01/2006 | EP1621551A1 Use of LLT1 and/or CD161 for modulating the activity of cells of the immune system |
| 02/01/2006 | EP1621549A2 Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621545A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 02/01/2006 | EP1621213A1 Ocular gene therapy |
| 02/01/2006 | EP1621212A1 Formulations comprising antisense nucleotides to connexins |
| 02/01/2006 | EP1621208A1 DNA vaccination for treatment of autoimmune disease |
| 02/01/2006 | EP1621207A2 Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors |
| 02/01/2006 | EP1621206A1 Chimeric cytokines and uses thereof |
| 02/01/2006 | EP1621205A1 Antimicrobial peptides derived from CAP18 |
| 02/01/2006 | EP1621204A1 Use of products derived from selenoprotein T in the context of calcium homeostasis |
| 02/01/2006 | EP1621203A1 RNAIII-inhibiting peptides for treating HIV infection |
| 02/01/2006 | EP1621077A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 02/01/2006 | EP1620679A2 Non-catalytic combustor for reducing nox emissions |
| 02/01/2006 | EP1620564A2 Methods of treating diseases responsive to induction of apoptosis and screening assays |
| 02/01/2006 | EP1620554A2 Recombinant fel d 1 allergen |
| 02/01/2006 | EP1620552A2 Use of glycodendrimer reagents for inhibiting adhesion by microorganisms |
| 02/01/2006 | EP1620547A2 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| 02/01/2006 | EP1620545A2 Disease prevention and vaccination following thymic reactivation |
| 02/01/2006 | EP1620466A2 Secreted protein family |
| 02/01/2006 | EP1620465A2 Insulin analogs having protracted time action |
| 02/01/2006 | EP1620464A1 Combined use of keratinocyte growth factor agonists and gastrin compounds |
| 02/01/2006 | EP1620463A2 Compositions and methods comprising a ligand of chemerin receptor |
| 02/01/2006 | EP1620462A2 Nogo- b, a regulator of endothelial cell function and vessel remodeling |
| 02/01/2006 | EP1620461A2 Group 1 mite polypeptide variants |
| 02/01/2006 | EP1620459A2 An intracellular estradiol binding protein, a polynucleotide encoding the same and cell lines overexpressing the same |
| 02/01/2006 | EP1620456A2 Hla-a2 tumor associated antigen peptides and compositions |
| 02/01/2006 | EP1620182A1 Methods for treating sinus headache |
| 02/01/2006 | EP1620145A2 A method for altering insulin pharmacokinetics |
| 02/01/2006 | EP1620135A1 In vivo imaging using peptide derivatives |
| 02/01/2006 | EP1620133A1 Gene therapy for neurometabolic disorders |
| 02/01/2006 | EP1620132A1 Biological pacemaker |
| 02/01/2006 | EP1620130A1 Prodrugs cleavable by cd26 |
| 02/01/2006 | EP1620126A2 Disease prevention and vaccination prior to thymic reactivations |
| 02/01/2006 | EP1620125A2 Tolerance to graft following thymic reactivation |
| 02/01/2006 | EP1620124A2 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 02/01/2006 | EP1620123A2 Genetic modification of targeted regions of the cardiac conduction system |
| 02/01/2006 | EP1620122A1 Use of a peptide that interacts with alpha v beta3 integrin of endothelial cell |
| 02/01/2006 | EP1620121A2 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells |
| 02/01/2006 | EP1620120A2 Long acting biologically active conjugates |
| 02/01/2006 | EP1620119A2 Use of b7-h3 as an immunoregulatory agent |
| 02/01/2006 | EP1620118A2 Reversible pegylated drugs |
| 02/01/2006 | EP1620117A2 Improved antitumoral treatments |
| 02/01/2006 | EP1620073A1 Absorption enhancers such as e.g. bht, bha or propyl gallate |
| 02/01/2006 | EP1620072A1 Zinc-containing sustained-release composition, its preparation, and method for producing the same |
| 02/01/2006 | EP1620061A2 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 02/01/2006 | EP1620060A2 Methods and devices for the sustained release of multiple drugs |
| 02/01/2006 | EP1620058A2 Composition for improving cognition and memory |
| 02/01/2006 | EP1620057A2 Modified heat-generating cosmetic compositions |
| 02/01/2006 | EP1620056A2 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 02/01/2006 | EP1619958A1 Peptides having an ace inhibiting effect |
| 02/01/2006 | EP1619952A2 Tolerance to graft prior to thymic regeneration |
| 02/01/2006 | EP1534825A4 Human analogs of murine deubiquitinating protease genes |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1343492B1 Treatment of mucositis |
| 02/01/2006 | EP1268502B1 O-aryl glucoside sglt2 inhibitors and method |